DaVita Inc.(DVA)
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Latest News & Analysis
DaVita Q3 Earnings Validate Clinical Strategy Amid Cost Inflation
Q3 results validate mortality strategy with volume stabilisation offsetting labour and pharmaceutical cost pressures.
DaVita Charts Clinical Course Amid Leverage: Middle Molecule Trials Mark Innovation Pivot
DaVita launches two clinical trials to evaluate middle-molecule clearance in dialysis, positioning the provider as innovation leader amid financial constraints.
DaVita's 2025 Outlook: Navigating Kidney Care Challenges
A comprehensive update on [DVA]'s earnings, stock plunge, and strategic shifts amid rising costs and regulatory pressures.
DaVita’s 2025 Outlook: Berkshire Sale and Rising Costs Impact DVA
An in-depth analysis of DaVita's weak 2025 earnings outlook amid rising care costs and Berkshire Hathaway’s reduced stake.
DaVita's 2025 Outlook: Stock Plummets as Costs Rise and Buffett Trims Stake
DaVita (DVA) faces market headwinds amid a stock decline and Berkshire Hathaway's reduced stake, prompting concerns about its 2025 earnings outlook.
DaVita Inc. (DVA) Market Analysis: Strategic Growth, Debt Management, and Latin America Expansion
DaVita advances value-based care with KCC model, strengthens balance sheet via $1B senior notes, and expands in Latin America amid competitive US dialysis market.
DaVita Inc. (DVA) Comprehensive Market Analysis: Financial Performance and Strategic Positioning
Explore DaVita Inc.'s latest financial results, strategic moves, and market positioning with data-driven insights on revenue growth and debt management.
DaVita Inc. (DVA) Financial Strategy and Market Position Analysis
Comprehensive analysis of DaVita Inc.'s financial strategy, international growth, debt management, and market positioning for investors.
DaVita Inc. Q2 2025 Earnings Beat Highlights Operational Resilience and Strategic Growth
DaVita Inc. Q2 2025 earnings beat expectations with $3.38B revenue and $2.95 EPS, underscoring strong operational resilience amid industry challenges.
DaVita Inc. Q2 2025 Earnings Analysis: Operational Resilience Amid Strategic Challenges
DaVita's Q2 2025 earnings beat expectations with a 6.1% revenue rise and EPS of $2.95, but stock dipped amid cybersecurity costs and volume concerns.
DaVita Inc. (DVA): Capital Allocation Under Strain as Buybacks Meet Rising Debt Costs
DaVita’s Q2 shock: rising interest costs and a cyber-related volume hit collided with aggressive buybacks — net debt/FCF now ~+7.66x and equity collapsed. What this means.
DaVita Inc. (DVA): Q2 Beat Masked by $13.5M Cyber Cost and Balance-Sheet Strain
DaVita reported a Q2 beat but disclosed **$13.5M** in direct cyber costs and an estimated **$40–$50M** revenue hit; leverage and buybacks now reshape risk dynamics.